STAAR Surgical Company designs, develops, manufactures, markets and sells implantable eye lenses and supplemental delivery systems for placing the lenses in the eye. The company is headquartered in Lake Forest, California.
| Revenue (TTM) | $328.27M |
| Gross Profit (TTM) | $241.46M |
| EBITDA | $31.23M |
| Operating Margin | 6.64% |
| Return on Equity | 0.15% |
| Return on Assets | 2.96% |
| Revenue/Share (TTM) | $6.55 |
| Book Value | $7.49 |
| Price-to-Book | 3.56 |
| Price-to-Sales (TTM) | 3.85 |
| EV/Revenue | 3.557 |
| EV/EBITDA | 35.31 |
| Quarterly Earnings Growth (YoY) | -38.50% |
| Quarterly Revenue Growth (YoY) | -12.00% |
| Shares Outstanding | $50.20M |
| Float | $26.16M |
| % Insiders | 0.85% |
| % Institutions | 111.38% |
Volatility is currently contracting
STAAR Surgical NASDAQ: STAA reported lower third-quarter sales and profit on a reported basis, but said revenue rose 21% after excluding a prior-year deferred sales item in China. The implantable lens maker also said demand for higher-priced products in China exceeded its ability to supply them during the quarter.
STAAR Surgical Company (STAA) Q3 2026 Earnings Call Transcript
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA), the global leader in phakic IOLs with the EVO™ family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today reported results for the third quarter ended October 2, 2026. The Company will host an earnings call and webcast today at 5:30 PM Eastern Time. Third Quarter and Year-to-Date 2026 Highlights Include: Net sales down 12% Y/Y; up 21% excluding a 33-percentage point ($25.9.
Staar Surgical (STAA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NEW YORK, Oct. 21, 2026 /PRNewswire/ -- Levi & Korsinsky announces that it has commenced an investigation of STAAR Surgical Company (NASDAQ: STAA) concerning possible breaches of fiduciary duties. If you are a current shareholder of STAA, you can request additional information here: https://zlk.com/cases/staar-surgical-company-class-action-lawsuit-staa-3 or contact Joseph E.
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO™ family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today released a new report entitled The Future of Refractive Surgery, the first comprehensive global market analysis showing a consistent, multi-market migration toward implantable lens correction driven by durable tailwinds on the demand and clinical sides of the market. The report examines patient.
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced the appointment of David Bailey as Chief Commercial Officer. Mr. Bailey will join STAAR's executive committee and report to Warren Foust, President and Chief Executive Officer. "David Bailey doesn't just know STAAR, he helped change the trajectory of the entir.
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced the appointment of Ben Park, Ph.D., as Chief Technology Officer. Dr. Park will join STAAR's Executive Committee and report to Warren Foust, President and Chief Executive Officer. "Evolving STAAR from a single-product focus into a multi-product platform is cent.
Review Staar Surgical's (STAA) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
STAAR Surgical NASDAQ: STAA reported second-quarter 2026 net sales of $93.5 million, up 111% from $44.3 million a year earlier, as growth in China, the Americas and parts of Europe contributed to what President and Chief Executive Officer Warren Foust called the company's strongest first half of revenue performance.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on STAA and any ticker you trade — then tracks every position and per-strategy win rate.
